Idenix Pharmaceuticals Reports Second Quarter and Six Month 2012 Financial Results and HCV Program Update
August 08, 2012 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Prices Public Offering of Common Stock
August 02, 2012 09:22 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
July 31, 2012 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 31, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG
July 31, 2012 07:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 31, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
IDX719 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
July 25, 2012 08:30 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 25, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
July 03, 2012 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., July 3, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 7th Annual JMP Securities...
Idenix Announces Positive Clinical Data for HCV Drug Candidates IDX184 and IDX719
June 19, 2012 16:06 ET
|
Idenix Pharmaceuticals
In an Interim Analysis From an Ongoing Phase IIb Clinical Trial of IDX184, an HCV Nucleotide Inhibitor, 89% of Patients Who Completed an Additional 12 Weeks of Pegylated Interferon Plus Ribavirin...
Idenix Pharmaceuticals to Present at the Wells Fargo Securities 2012 Healthcare Conference
June 13, 2012 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will participate in a fireside chat at the Wells Fargo...
Idenix Pharmaceuticals Reports First Quarter 2012 Financial Results and HCV Development Program Progress
May 02, 2012 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., May 2, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
April 30, 2012 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Deutsche Bank 37th...